Scarica l'app Stockscreener
1.575
2.48%
-0.035
Precedente Chiudi:
$1.61
Aprire:
$1.63
Volume 24 ore:
1.05M
Relative Volume:
0.26
Capitalizzazione di mercato:
$417.95M
Reddito:
$194.75M
Utile/perdita netta:
$-51.26M
Rapporto P/E:
-5.625
EPS:
-0.28
Flusso di cassa netto:
$-23.38M
1 W Prestazione:
-5.42%
1M Prestazione:
+6.80%
6M Prestazione:
-56.75%
1 anno Prestazione:
-17.37%
Intervallo 1D:
$1.56
$1.63
Intervallo di 1 settimana:
$1.56
$1.66
Portata 52W:
$1.445
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Confronta AKBA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.575 | 427.24M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
125.45 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.61 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.02 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.66 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
492.08 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-28 | Iniziato | Leerink Partners | Outperform |
| 2025-04-01 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Ripresa | BTIG Research | Buy |
| 2023-08-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Akebia Therapeutics expands portfolio beyond anemia with new rare kidney disease pipeline centered on AKB-097 and praliciguat - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - Quantisnow
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat - Finviz
Dow Update: Can Akebia Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Reactions & Accurate Intraday Trade Tips - moha.gov.vn
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN
Can Akebia Therapeutics Inc. stock outperform in 2025 bull market2025 Price Targets & Free Safe Capital Growth Stock Tips - Улправда
Why Akebia Therapeutics Inc. (AX9) stock gets analyst attention2025 Performance Recap & Stepwise Trade Signal Implementation - Улправда
What insider trading reveals about Akebia Therapeutics Inc. stockTreasury Yields & Accurate Intraday Trade Tips - Улправда
Is Akebia Therapeutics Inc. stock a buy for dividend growthPrice Action Analysis & Swing Trade Smarter With Data Insights - Bollywood Helpline
Volume Report: Can Akebia Therapeutics Inc. stock outperform in 2025 bull market - Улправда
Why Akebia Therapeutics Inc. stock is a must watch in 2025July 2025 Momentum & Fast Moving Market Watchlists - Улправда
Is Akebia Therapeutics Inc. stock safe for conservative investorsJuly 2025 Price Swings & Stepwise Swing Trade Plans - Улправда
How Akebia Therapeutics Inc. stock performs in weak economyWeekly Trend Summary & Daily Technical Forecast Reports - Улправда
Can Akebia Therapeutics Inc. stock deliver sustainable ROEEarnings Overview Report & Expert Curated Trade Setup Alerts - Улправда
Why Akebia Therapeutics Inc. stock is considered a top pickGlobal Markets & Free Community Supported Trade Ideas - Bölüm Sonu Canavarı
Is Akebia Therapeutics Inc. stock affected by interest rate hikes2025 Retail Activity & Technical Buy Zone Confirmation - DonanımHaber
Is Akebia Therapeutics Inc. (AX9) stock considered safe havenJuly 2025 Spike Watch & Accurate Trade Setup Notifications - DonanımHaber
Why Akebia Therapeutics Inc. (AX9) stock attracts HNW investorsVolume Spike & Weekly Momentum Stock Picks - Улправда
Is Akebia Therapeutics Inc. (AX9) stock a top pick for value investorsMarket Growth Review & Weekly Breakout Stock Alerts - Улправда
Will Akebia Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Final Week & Community Consensus Trade Signals - Улправда
Aug Big Picture: Is Akebia Therapeutics Inc. stock safe for conservative investorsGold Moves & Safe Capital Growth Plans - Улправда
Is Akebia Therapeutics Inc. stock a buy on dipsWeekly Profit Recap & Consistent Return Strategy Ideas - Улправда
Activity Recap: What insider trading reveals about Akebia Therapeutics Inc. stockLayoff News & Detailed Earnings Play Alerts - Улправда
Why analysts recommend Akebia Therapeutics Inc. (AX9) stock2025 Earnings Impact & Advanced Swing Trade Entry Plans - ulpravda.ru
Market Moves: Is Akebia Therapeutics Inc. stock a buy on dipsAnalyst Downgrade & Capital Efficiency Focused Ideas - Улправда
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Akebia Therapeutics Earnings Notes - Trefis
Akebia Therapeutics (FRA:AX9) OCF Margin % : 47.82% (As of Sep. 2025) - GuruFocus
Akebia Therapeutics announces establishment of rare kidney disease pipeline - MSN
Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why Akebia Therapeutics Inc AX9 stock attracts HNW investorsPortfolio Return Report & Reliable Entry Point Alerts - moha.gov.vn
Will Akebia Therapeutics Inc. (AX9) stock sustain dividend payoutsNew Guidance & Free Technical Pattern Based Buy Signals - Newser
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront - MSN
Is Akebia Therapeutics Inc. (AX9) stock testing key support2025 Key Highlights & Free Real-Time Volume Trigger Notifications - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Akebia Therapeutics, Inc. (AKBA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Pfizer-backed biotech lands $120M, plus other Boston-area life science news - The Business Journals
Deal Watch: Akebia Gets Phase II Alopecia Areata Candidate From Cost-Conscious Q32 - Citeline News & Insights
Akebia Therapeutics (NASDAQ:AKBA) Receives Buy Rating from BTIG Research - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Why Akebia Therapeutics Inc. (AX9) stock could be top winnerQuarterly Profit Report & Free Weekly Watchlist of Top Performers - Newser
HC Wainwright & Co. Reiterates Akebia Therapeutics (AKBA) Buy Recommendation - MSN
BTIG Reiterates Buy Rating for Akebia Therapeutics (AKBA) | AKBA Stock News - GuruFocus
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? - Yahoo Finance
Akebia Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
HC Wainwright & Co. Reiterates Buy Rating for AKBA, Price Target Unchanged | AKBA Stock News - GuruFocus
QTTB Stock Explodes Nearly 95%: Akebia Deal Transforms Q32 Bio’s Future - Bitget
Is Akebia Therapeutics Inc a good long term investmentStock Market Trends & Access Free Tools and Start Investing - earlytimes.in
Can Akebia Therapeutics Inc. (AX9) stock sustain revenue momentumEarnings Overview Summary & Low Risk High Reward Ideas - Newser
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.43%
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):